Skip to content

Study · Case report or series · n = 1 · 2021

1 result

Oxytocin-Induced Acute Pulmonary Edema: A Case Report and Literature Review.

Mansour MK, Dehelia M, Hydoub YM, Kousa O, Hassan B

Cureus16 May 2021

PMID34141511 (opens in a new tab)PMCIDPMC8206651 (opens in a new tab)DOI10.7759/cureus.15067 (opens in a new tab)PepBankPUB-34141511
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

The use of intravenous (IV) oxytocin has been commonly associated with the development of nausea, vomiting, headache, flushing, and hypotension. To date, only a few previously published studies have linked the administration of IV oxytocin, in high doses exceeding 15 mU/min, with the development of acute pulmonary edema. In this article, we aim to report the rare occurrence of acute pulmonary edema following administration of IV oxytocin at a small dose of 2 mU/min, in a 20-year-old pregnant female, to allow its recognition and prompt treatment by the clinician caring for the patient.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 20-year-old pregnant woman, intravenous oxytocin at 2 mU/min was followed by acute pulmonary edema.

    In plain wordsIn one 20-year-old pregnant woman, a small intravenous dose of oxytocin was followed by fluid in the lungs.

    Peptide
    Oxytocin
    Outcome
    IncreaseAcute pulmonary edema after IV oxytocin
    Study

    n = 1

    Outcome group
    Adverse events · Respiratory
    Studied dose
    2 mU/min · intravenousAs given in this study (human).

    Source sentences

    Summary
    In this article, we aim to report the rare occurrence of acute pulmonary edema following administration of IV oxytocin at a small dose of 2 mU/min, in a 20-year-old pregnant female, to allow its recognition and prompt treatment by the clinician caring for the patient.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.